FFPE HPV Characterized

HPV infection has been reported to correlate with several cancer types, especially squamous cell carcinomas originating from head and neck (H&N) as well as cervix tissues. HPVs are classified by genotype, and at least 130 types have been identified by sequencing the gene encoding the major capsid protein L1. High-risk genotypes 16 and 18 are associated with 70% of cervical, and about 80% HPV positive vulval and vaginal carcinoma.

Targeting high-risk HPV mRNA from the E6/E7 oncogenes, which are essential for development of cervical cancer, DiaCarta’s QuantiVirus™ HPV mRNA Test detects HPV oncogenes E6/E7 mRNA from 14 high-risk type (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and genotypes HPV 16 and HPV 18 directly from cervical samples for cervical cancer screening. Using Diacarta’s QuantiVirus HPV E6/E7 RNA test, BioChain offers HPV-characterized H&N and cervix squamous cell carcinoma tissue sections from various donors as control slides for scientists in this field of study.  Both positive and negative samples are available.

Learn more

FFPE HPV Characterized

The QuantiVirus™ HPV E6/E7 RNA Assay (bDNA) is a sandwich nucleic acid hybridization procedure to detect HPV E6/E7 mRNA in cervical samples without RNA purification or RT-PCR. After HPV mRNA is released from the cells by lysis, the RNA is captured onto a microwell by a set of target-specific, synthetic oligonucleotide capture extenders. Another set of target-specific, synthetic oligonucleotides called label extender hybridizes to both the viral mRNA from the HPV genome and the synthetic pre-amplifier probes. The pre-amplifier probe subsequently hybridizes to an amplifier probe forming a branched DNA (bDNA) complex. Multiple copies of an alkaline phosphatase (AP) labeled probe are then hybridized to the immobilized amplifier probe. Detection is achieved by incubating the AP-bound complex with a chemiluminescent substrate. Light emission is directly related to the amount of HPV RNA present in each sample, and results are recorded as relative light units (RLUs) by the DiaCarta QuantiVirus Luminometer. A positive control is defined by light emission from control sample containing known concentrations of E6/E7 mRNA. When needed, concentrations of HPV RNA in specimens can be estimated from this positive control. A result of “positive” or “negative” is generated based on relative light units (RLUs) from oral samples over the RLUs from background.


Our team of scientists are here to help!